Regimen Reference Order – LYMP – zanubrutinib

ARIA: LYMP – [zanubrutinib]

Planned Course: **Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)**
Indication for Use: **Waldenström's Macroglobulinemia**

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than 0.75 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L

- **Contact Hematologist if parameters not met**

***Note:* Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LYMP – zanubrutinib

Drug	Dose	CCMB Administration Guideline
zanubrutinib	320 mg*	Orally once daily with or without food Swallow whole **(Self-administered at home)**
*Alternate dosing schedule of 160 mg twice daily may be used at the prescriber's discretion		
zanubrutinib (BRUKINSA®) available dosage strength: 80 mg capsule **Classification: Cytotoxic, Hazardous**		

REQUIRED MONITORING

Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

Cardiac monitoring

- EKG at baseline
- Monitor blood pressure and heart rate for tachycardia and irregular rhythm at every clinic visit
- At physician's discretion, EKG to assess for atrial fibrillation if tachycardia or irregular rhythm present

Throughout treatment

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders
  - Every 2 to 4 weeks for the first 6 months, then
  - Every 12 weeks and as clinically indicate

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS FOR PATIENT

- Patients should report signs and symptoms of bleeding (i.e. excess bruising), palpitations, syncope and skin changes
- Patients should use necessary sun protection due to a potential increased risk of skin cancer
- When zanubrutinib is prescribed twice daily, doses of zanubrutinib should be separated by approximately 12 hours
- zanubrutinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood, and body fluids while on zanubrutinib

ADDITIONAL INFORMATION

- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy ***Hepatitis B Monitoring for Oncology and Hematology Patients*** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- Hematologist should be consulted regarding dosing of zanubrutinib pre- and post-surgery for patients undergoing a surgical procedure, including dental surgery, due to risk of bleeding regardless of platelet count